CARDIOPATCH News

New cell therapies and organ regeneration techniques are boosting regenerative medicine

 

  • CARDIOPATCH project partner FIRHSCSP organized the 23th of June a virtual event to overview the best practices in stem-cell therapy and discuss the hurdles that need to be overcome to implement it in the clinical setting
  • Nuria Montserrat, group leader at the Institute for Bioengineering of Catalonia, took part in the event with her presentation about the growing opportunities of pluripotency

     

Which are the best practices in actual regenerative medicine? What opportunities open these new therapies and techniques? These questions were answered by different hematology and tissue engineering experts in the ‘Best Practices in Regenerative Medicine’ event that took place virtually the 23th of June organized by the CARDIOPATCH Project partner FIRHSCSP (Fundació Institut de Recerca Hospital de la Santa Creu i Sant Pau). 

The online conference presented the best practices in stem-cell therapy and organ regeneration and it was an opportunity to open a discussion between different specialists about the hurdles that need to be overcome to implement these techniques in the clinical setting. 

At 10:00 CET, Javier Briones, researcher from the Hematology Service of Hospital de la Santa Creu i Sant Pau, was responsible for starting the meeting with its presentation of the CAR-T cell therapy.  

He presented the design and evolution that follows this therapy and the process that has to be taken for its production and final commercialization. In addition, Briones explained the efficiency of the CAR-T cell therapy against Hodgkin lymphoma. 

“CAR-T enriched cells induce a potent antitumor response against systemic human Hodgkin lymphoma xenograft”, said Briones. 

After his presentation, Gemma Arderiu, Doctor from the CARDIOPATCH partner FIRHSCSP introduced the audience to the obtention and miRNA regulation of ASCs to induce endothelial differentiation for therapeutic application. 

“Delivery of ASCs promotes collateral artery formation and angiogenesis after ligation of femoral artery in mouse hind limbs”, explained Arderiu after giving a presentation of what is cell culture, which is the growth of cells from an animal or plant in an artificial controlled environment. 

To end the virtual event, Nuria Montserrat, group leader at the Institute for Bioengineering of Catalonia, presented the growing opportunities of pluripotency for the regeneration of organs. 

The expert presented different bioengineering strategies like bioprinting or decellularization for the regeneration of cardiac tissues giving examples and a timeline of milestones in the success of these kinds of techniques. 

For example, she showcased the results and strategies that have been followed in the BRAVE cardiac regenerative medicine European initiative.

This meeting is part of the program of actions designed by the CARDIOPATCH initiative to promote scientific dissemination and bring to the agents involved in the field of health and medicine the benefits of research.

Co-funded by the EU Interreg Sudoe Programme, via the European Regional Development Fund (ERDF), CARDIOPATCH project (Network of Excellence for the development of Advanced Therapies of Myocardial Infarction treatment based on regenerative medicine and 3D printing) is investigating new treatments for myocardial infarction to provide solutions to improve patients’ quality of life.

The initiative is focused on developing a stem-cell smart patch able to regenerate tissues damaged by infarction. The patch is currently in the first phase of a clinical trial on patients with chronic ischaemic cardiomyopathy. The project also aims to develop a roll-up 3D device which will allow the patch implantation in the heart through less invasive methods and a 3D system to generalize the patch’ production and streamline transport.

Coordinated by Clínica Universidad de Navarra (CUN), the project includes partners from Spain, France and Portugal. Alongside of CUN, the consortium is made up by CIMA Universidad de Navarra, via the Foundation for Applied Medical Research, Leartiker Technology Center, Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau, communication agency GUK, Centre Hospitalier Universitaire de Toulouse, the University of Montpellier (UM) - Institut des Biomolécules Max Mousseron (IBMM), GenIbet Biopharmaceuticals and the Instituto de Biologia Experimental e Tecnológica.

Cardiopatch Project

CARDIOPATCH Excellent Network born to advance in the field of Cardiac Regenerative Medicine and 3D printing applied to Myocardial Infarction treatment.

CARDIOPATCH project is co-funded by the Interreg Sudoe Programme through the European Regional Development Fund (ERDF).

CARDIOPATCH project is co-funded by the Interreg Sudoe Programme through the European Regional Development Fund (ERDF).

Recent tweets

Los valores de #CARDIOPATCHProject describen la filosofía de trabajo de sus miembros y reflejan la visión colaborativa y su misión.

#CARDIOPATCH es…

✨Inspirador y dinámico
✨Abierta
✨Apasionado
✨Participativa
✨Excelente

👉 https://bit.ly/3hnzxMb

#Interreg

#CARDIOPATCHProject’s values describe the work philosophy of its founder’ members and reflect the joint vision and mission statements.

#CARDIOPATCH is...

✨Inspiring and dynamic
✨Open
✨Passionate
✨Engaging
✨Excellent

👉 https://bit.ly/3hnzxMb

#Interreg

#NUEVOEVENTO | No te pierdas la nueva edición de #BiomedicaOnTheMove el 25 de mayo.

Descubre las aplicaciones médicas del futuro y encuentra oportunidades de networking en el evento virtual.

Regístrate aquí 👉 https://bit.ly/3tCxVRc

Load More...

2021 © cardiopatch.eu. Legal notice / Privacy policy / Cookies policy